

## Publikationen 2021

1. Specker C, Alberding A, Aringer M, Burmester GR, Flacke JP, Hofmann MW, Kästner P, Kellner H, Moosig F, Sieburg M, Tony HP, Fliedner G. ICHIBAN, a non-interventional study evaluating tocilizumab long-term effectiveness and safety in patients with active rheumatoid arthritis. **Clin Exp Rheumatol** 2021; 39:319-328.
2. Maher TM, Mayes MD, Kreuter M, Volkmann ER, Aringer M, Castellvi I, Cutolo M, Stock C, Schoof N, Alves M, Raghu G; SENSISCIS trial investigators. Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of the SENSISCIS trial. **Arthritis Rheumatol** 2021; 73: 671-676.
3. Kernder A, Richter JG, Fischer-Betz R, Winkler-Rohlfing B, Brinks R, Aringer M, Schneider M, Chehab G. Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort. **Lupus** 2021; 30: 431-438.
4. Aringer M, Brinks R, Dörner T, Daikh D, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Cziráj L, Doria A, Graninger WB, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Costenbader KH, Johnson SR. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE Classification Criteria Item Performance. **Ann Rheum Dis** 2021; 80: 775-781.
5. Benad M, Koschel D, Herrmann K, Wiefel K, Kleymann A, Aringer M. Effects of cyclophosphamide and rituximab in patients with connective tissue diseases with severe interstitial lung disease. **Clin Exp Rheumatol** 2021; Feb 25 Epub.
6. Behrens F, Koehm M, Rossmann T, Alten R, Aringer M, Backhaus M, Burmester GR, Feist E, Herrmann E, Kellner H, Krueger K, Lehn A, Müller-Ladner U, Rubbert-Roth A, Tony HP, Wassenberg S, Burkhardt H. Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study). **Rheumatology (Oxford)** 2021; Mar 19 Epub.

7. Mucke J, Alarcon-Riquelme M, Andersen J, Aringer M, Bombardieri S, Brinks R, Cervera R, Chehab G, Cornet A, Costedoat-Chalumeau N, Czirják L, Doria A, Fischer-Betz R, Furie RA, Gatto M, Houssiau FA, Ines L, Liang MH, Morand E, Mosca M, Pego-Reigosa JM, Rúa-Figueroa I, Ruiz-Irastorza G, Terrier B, Voss A, Schneider M. What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. **Lupus Sci Med** 2021; 8: e000506.
8. Chavatza K, Kostopoulou M, Nikolopoulos D, Gioti O, Togia K, Andreoli L, Aringer M, Boletis J, Doria A, Houssiau FA, Jayne D, Mosca M, Svenungsson E, Tincani A, Bertias G, Fanouriakis A, Boumpas DT. Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. **Ann Rheum Dis** 2021; 80: 1175-1182.
9. Albrecht K, Redeker I, Aringer M, Marschall U, Strangfeld A, Callhoff J. Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort. **Lupus Sci Med** 2021; 8: e000526.
10. Felten L, Leuchten N, Aringer M. Glucocorticoid dosing and relapses in giant cell arteritis-a single center cohort study. **Rheumatology (Oxford)** 2021; Sep 6 Epub.
11. Kiltz U, Buschhorn-Milberger V, Albrecht K, Lakomek HJ, Lorenz HM, Rudwaleit M, Schneider M, Schulze-Koops H, Aringer M, Hasenbring MI, Herzer P, von Hinüber U, Krüger K, Lauterbach A, Manger B, Oltman R, Schuch F, Schmale-Grede R, Späthling-Mestekemper S, Zinke S, Braun J. Entwicklung von Qualitätsstandards für die Versorgung von Patient\*innen mit rheumatoider Arthritis zur Anwendung in Deutschland. **Z Rheumatol** 2021; Oct 15 Epub.
12. Stone JH, Spotswood H, Unizony SH, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. **Rheumatology (Oxford)** 2021 Oct 29 Epub.
13. Kernder A, Düsing C, Richter J, Brinks R, Fischer-Betz R, Winkler-Rohlfing B, Aringer M, Schneider M, Chehab G. Factors detrimental to work productivity and daily activities in systemic lupus erythematosus patients - Analysis of the German LuLa study. **Lupus** 2021; 30: 1931-1937.
14. van Vollenhoven RF, Bertias G, Doria A, Isenberg D, Morand E, Petri MA, Pons-Estel BA, Rahman A, Ugarte-Gil MF, Voskuyl A, Arnaud L, Bruce IN, Cervera R, Costedoat-Chalumeau N, Gordon C, Houssiau FA, Mosca M, Schneider M, Ward MM, Alarcon G, Aringer M, Askenase A, Bae SC, Bootsma H, Boumpas DT, Brunner H, Clarke AE, Coney C, Czirják L, Dörner T, Faria R, Fischer R, Fritsch-Stork R, Inanc M, Jacobsen S, Jayne D, Kuhn A, van Leeuw B, Limper M, Mariette X, Navarra S, Nikpour M, Olesinska MH, Pons-Estel G, Romero-Diaz J, Rubio B, Schoenfeld Y, Bonfá E, Smolen J, Teng YKO, Tincani A, Tsang-A-Sjoe M, Vasconcelos C, Voss A, Werth VP, Zakharhova E, Aranow C. 2021 DORIS

definition of remission in SLE: final recommendations from an international task force. **Lupus Sci Med** 2021; 8: e000538.

15. Specker C, Aringer M, Burmester GR, Killy B, Hofmann MW, Kellner H, Moosig F, Tony HP, Fliedner G. The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. **Clin Exp Rheumatol** 2021; Nov 22 Epub.
16. Desideri G, Rajzer M, Gerritsen M, Nurmohamed MT, Giannattasio C, Tausche AK, Borghi C. Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study. **Eur Heart J Cardiovasc Pharmacother** 2021; Jan 7 Epub.
17. Lenk J, Matthé E, Pillunat LE, Aringer M. Systemischer Lupus erythematodes durch Tumornekrosefaktor-Blocker – Eine seltene Nebenwirkung einer Uveitis-intermedia-Therapie. Impact factor 1,059. **Ophthalmologe** 2021; Aug 30 Epub.
18. Aringer M, Baerwald C, Bergner R, Feuchtenberger M, Gebhardt C, Hagen M, Keyßer G, Lorenz HM, Witte T. Rheumatologie im Medizinstudium. **Z Rheumatol** 2021; 80: 2-8.
19. Aringer M, Johnson SR. New lupus criteria: a critical view. **Curr Opin Rheumatol** 2021; 33: 205-210.
20. Aringer M, Schneider M. Systemischer Lupus erythematodes. **Internist (Berl)** 2021; 62: 385-396.
21. Aringer M, Riemekasten G. Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. **Best Pract Res Clin Rheumatol** 2021; 35: 101672.
22. Rodionov RN, Biener A, Spieth P, Achleitner M, Hölig K, Aringer M, Mingrone G, Corman VM, Drosten C, Bornstein SR, Tonn T, Kolditz M. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. **Lancet Microbe** 2021; 2:e 138. doi: 10.1016/S2666-5247(21)00030-6.
23. Aringer M, Tektonidou MG, Boumpas D, Houssiau F. European League Against Rheumatism (EULAR) recommendations and EULAR/American College of Rheumatology criteria-documenting progress in lupus. **Rheumatology (Oxford)** 2021; 60: 2976-2978.
24. Aringer M, Schneider M. Systemischer Lupus erythematodes. **Hautarzt** 2021; 72: 337-348.
25. Wiefel K, Aringer M. Polyarthritiden – vom Symptom zur Diagnose. **Dtsch Med Wochenschr** 2021; 146: 582-590.
26. Aringer M. Systemic lupus erythematosus does not prevent antibody responses to SARS-CoV-2. **Lancet Rheumatol** 2021; 3: e538-e540.
27. Aringer M, Johnson SR. Systemic lupus erythematosus classification and diagnosis. **Rheum Dis Clin North Am** 2021; 47: 501-511.

28. Aringer M, Koschel D, Krause A, Schneider U, Gläser S. Moderne medikamentöse Therapie der interstitiellen Lungenerkrankung bei systemischer Sklerose. **Dtsch Med Wochenschr** 2021; Dec 3 Epub.
29. Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. **Lancet Rheumatol** 2021; 3: e58-e70. Impact factor 8,136.
30. Tausche AK. Gicht. **Internist (Berl)** 2021; 62: 513-525.
31. Erlar A, Fiedler J, Koch A, Heldmann F, Schütz A. **Arthritis Rheumatol** 2021; 73: 2188.
32. Schierz JH, Sarikaya I, Wollina U, Unger L, Sarikaya A. Immune Checkpoint Inhibitor-Related Adverse Effects and 18F-FDG PET/CT Findings. **J Nucl Med Technol** 2021; 49: 324-329.